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Abstract
Purpose/results/discussion. Rearrangement of the EWS gene with an ETS oncogene by chromosomal translocation is a
hallmark of the Ewing family of tumors (EFT). Detectability, incidence, tumor speci® city and variability of this aberration
have been matters of intense investigation in recent years. A number of related alterations have also been found in other
malignancies. The common consequence of these gene rearrangements is the generation of an aberrant transcription
factor. In EFT, the ETS partner is responsible for target recognition. However, synergistic and possibly tissue-restricted
transcription factors interacting with either the EWS or the ETS portion may in¯ uence target selection. Minimal domains
of both fusion partners were de® ned that have proved necessary for the in vitro transformation of murine ® broblasts. These
functional studies suggest a role for aberrant transcriptional regulation of transforming target genes by the chimeric
transcription factors. Also, fusion of the two unrelated protein domains may affect overall protein conformation and
consequently DNA binding speci® city. Recent evidence suggests that EWS, when fused to a transcription factor, interacts
with different partners than germ-line EWS. Variability in EWS± ETS gene fusions has recently been demonstrated to
correlate with clinical outcome. This ® nding may re¯ ect functional differences of the individual chimeric transcription
factors. Alternatively, type and availability of speci® c recombinases at different time-points of stem cell development or in
different stem cell lineages may determine fusion type. Studies on EFT cell lines using EWS± ETS antagonists do suggest
a rate-limiting essential role for the gene rearrangement in the self-renewal capacity of EFT cells. The presence of
additional aberrations varying in number and type that may account for immortalization and full transformation is
postulated. Knowledge about such secondary alterations may provide valuable prognostic markers that could be used for
treatment strati® cation.
Key words: EWS, ETS, IGF1, tumor suppressor, prognosis.
Introduction
Ewing’s sarcoma (ES), being a rare malignant dis-
ease affecting bone and soft tissue in children and
young adults, was hardly known to people other
than pediatric oncologists until the characterization
of a chimeric gene product presumed to be causally
involved in the generation of this neoplasm. It dra-
matically gained attention when, from investigating
other malignancies, it became apparent that the
ES-derived oncoprotein constitutes the prototype of
a whole class of aberrant proteins speci® cally associ-
ated with certain tumor types. Consequently, ES
may be considered a model system to study malig-
nant conversion on a subclinical level. The discovery
of the ES-associated gene rearrangement transiently
halted a controversy among pathologists about the
existence of distinct categories of ES (i.e. osseous
ES, extra-skeletal ES, Askin tumor, peripheral
primitive neuroectodermal tumor) because it was
found to be expressed in all of them. Clinically,
however, there is a need for diversi® cation.
Although more than half of the patients can be
cured by multimodal therapy, one third of cases
with localized disease and about 80% of patients
presenting with metastases succumb to the disease
(for a recent review, see Kovar et al.
1). Current
treatment protocols have largely compensated for
classical prognostic markers such as tumor volume
and localization of the primary except for the rather
unfavorable presence of metastases at diagnosis. It is
likely, therefore, that biological differences exist
between so far incurable aggressive disease and clin-
ically manageable localized disease inexplicable by
the mere presence of the ES-associated gene
rearrangement. While Ewing’s tumor research has
focused on the clinical exploitability and the func-
tion of the ES-speci® c gene rearrangement since its
discovery in 1992, this review will also consider
extensively the role of additional molecular aberra-
tions in the search for useful prognostic markers.
Neoplastic transformation and metastatic spread is
commonly believed to result from a multi-step pro-
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cess. In this context, the ES-speci® c gene
rearrangement obviously constitutes a rate-limiting
event. According to Knudson’s legendary two-hit
hypothesis, at least one additional aberration
should be present in a Ewing tumor. It is possible
that this second hit is less speci® c and affects dif-
ferent genes at different times during development
of the enigmatic Ewing tumor stem cell, thus
de® ning distinct subcategories of the disease.
Consequently, Ewing tumor research is slowly
moving towards molecular subclassi® cation and
staging.
Diagnostic tools
In 1988, the cytogenetic translocation t(11;22)
(q24;q12) was described as speci® cally associated
with histopathologically diagnosed ES and periph-
eral primitive neuroectodermal tumor (pPNET).
2
The presence of this aberration in a largely undif-
ferentiated small round cell tumor of childhood
turned out to be a formidable diagnostic marker.
3,4
However, cytogenetic analysis was restricted to
tumor cells with at least limited in vitro prolifera-
tion potential. The generation of an antibody,
HBA71,
5 speci® cally reacting with the surface
glycoprotein encoded by the MIC2 gene,
6 which
was found to be abundantly present in tumor cells
carrying a chromosome 22q12 aberration,
7,8
enlarged the spectrum of diagnostic tools. How-
ever, embryonal rhabdomyosarcomas, asterocy-
tomas, neuroendocrine tumors and carcinomas
occasionally stained positive with HBA71
9 and,
when using a more sensitive antibody (12E7
10),
high level expression of this antigen was also noted
in early hematopoietic precursor cells
11 and several
lymphomas.
12 The characterization of the ES
break-point regions on chromosomes 22 and 11
13
and the subsequent cloning of a chimeric cDNA
resulting from a gene fusion between a novel gene,
designated EWS, and the ETS transcription factor
gene FLI1
14 allowed for sensitive detection of
tumor cells carrying a 11;22 translocation even
in small samples of fresh, frozen or paraf® n-
embedded material by means of reverse transcrip-
tase polymerase chain reaction (RT-PCR).
15± 18
Subsequently, several alternative fusion partners for
EWS from the ETS oncogene family were
identi® ed in ES and pPNET cases
19± 24 Using the
RT-PCR method, combined with genomic analysis
of the EWS break-point region, on a large series cf
osseous and extra-skeletal ES (including Askin
tumors and pPNET, designated Ewing family of
tumors (EFT)) as opposed to several unrelated
small round cell tumors, the speci® city of the
EWS± ETS gene rearrangement and the correlation
with high MIC2 expression was con® rmed.
16± 25
Recently, however, the limitation of this aberration
to typical EFT members has been questioned since
RT-PCR ampli® able EWS± FLI1 fusion transcripts
have been reported in childhood soft tissue sarco-
mas with mixed phenotype,
26± 27 in some olfactory
neuroblastomas
28 which have previously been
shown not to express MIC2,
29 and in two cases of
classical MIC2-negative neuroblastoma.
30 In the
absence of any cytogenetic evidence for a t(11;22)
in neuroblastoma the latter ® nding needs to
be independently con® rmed. On the other hand,
RT-PCR failed to demonstrate the presence of
chimeric EWS transcripts in roughly 5% of histo-
logically classi® ed EFT. Sceptics might raise their
® ngers and recall all the potential pitfalls of using
RT-PCR including the method’s inherent suscep-
tibility to cross-contamination as a single tool in
the diagnosis of histopathologically ambiguous
cases of small round cell tumors. Intriguing ques-
tions, i.e. if EWS± ETS gene rearrangements can
occur outside the EFT and if `atypical’ ES exist,
can only be assessed by the use of complementary
techniques allowing for the visualization of the
EWS gene rearrangement on a single cell level. It
has already been demonstrated that ¯ uorescent in
situ hybridization (FISH) using cosmids ¯ anking
the EFT break-point regions is not restricted to
metaphase chromosomes, but is also feasible to
detect the gene rearrangement ef® ciently on inter-
phase nuclei
31,32 (Hattinger et al., unpublished).
Alternatively, antibodies to unique domains of the
chimeric gene product could allow the routine
pathologist to screen for the EWS rearrangement
by standard immunohistochemical methods. The
author and others
125, 126 have recently obtained
preliminary indirect evidence from protein interac-
tion studies that an amino terminal EWS domain,
which appears to be inaccessible in germ-line
EWS, might be speci® cally exposed on the surface
of the chimeric product (see below). One could
endeavor, therefore, to generate an agent that dis-
tinctly recognizes the altered conformation of the
EWS portion present in EWS fusion proteins. The
hinge region of EWS± ETS chimeric proteins dis-
plays a high degree of variability due to variable
break-point locations in the genes contributing to
the translocation. So far, ® ve alternative ETS fam-
ily members have been found in EWS gene rear-
rangements. Therefore, antibodies to the linker
domain of fused partners would be of only limited
use in routine diagnosis. For the analysis of RT-
PCR negative `atypical’ EFT and for small round
cell tumors with a diagnosis other than EFT but
RT-PCR positive for an EWS chimeric transcript,
it is strongly recommended to con® rm the molecu-
lar diagnosis by the demonstration of an EWS
aberration on either DNA level (FISH or Southern
blot) or on RNA level by Northern blotting.
Presently, it cannot be excluded that using these
approaches, followed by re® ned cloning proce-
dures, further ETS family members will be
identi® ed as alternative fusion partners for EWS in
EFT or non-EFT.Molecular biology of Ewing tumors 5
Fig. 1. Generation of chimeric oncoproteins involving an EWS family member and a transcription factor. Protein domains presumably
involved in RNA binding (RGG boxes and RNP motif) are replaced by the DNA binding portion of the transcription factor. The minimal
domains of the fusion partners present in all chimeras are the carboxy terminal domain (CTD) of the EWS family member and the
DNA binding domain (DBD) of the transcription factor. The carboxy terminal transactivation domain (CTA) of the transcription
factor is lost in fusions of ETS family members but not of CHOP.
The EWS± ETS gene rearrangement
The EWS gene family
EWS is the prototype of a growing family of puta-
tive RNA-binding proteins including TLS (translo-
cated in liposarcoma)/FUS,
33± 35 hTAFII68 (TATA
box binding protein associated factor),
36 the small
nuclear ribonuclear protein(snRNP)-associated 69-
kDa protein,
37 the bovine Pigpen protein
38 and
Drosophila cabeza/SARFH (sarcoma associated
RNA binding ¯ y homologue),
39,40 that share dis-
tinct structural characteristics such as a conserved
RNA binding motif ¯ anked by arginine± glycine±
glycine (RGG) boxes
41 and a putative zinc-® nger
domain in the carboxy terminus. This portion is
replaced by the DNA binding domain of a tran-
scription factor in the oncogenic EWS and TLS
fusion proteins. The amino terminus is rich in
glutamine and proline residues. As such, it resem-
bles the activation domain of certain transcription
factors such as SP-1.
42 In EWS, this N-terminal
domain (NTD), which is encoded by the ® rst seven
exons,
43 is comprised of 30 copies of a repeated
degenerate peptide of 7± 12 residues rich in
tyrosine, serine, threonine, glycine and glutamine
44
(Fig. 1). TLS was identi® ed as a heterogenous
nuclear ribonucleoprotein (hnRNP) in non-
spliceosomal complexes on mRNA continuously
shuttling between the nucleus and the cytoplasm
45
and SARFH was found to be associated with
regions of the Drosophila chromatin transcribed by
RNA polymerase II. Consistent with a role of EWS
family members in gene transcription, hTAFII68,
TLS and EWS have been identi® ed in subpopula-
tions of the general transcription factor TFIID.
126
However, recent evidence suggests that the onco-
genic derivatives of TLS and EWS are not stably
associated with the RNA polymerase II complex
and TFIID.
126 Accumulation in nuclear inclusions
such as the coiled body and the nucleolus have
been reported for Pigpen,
46 the 69-kDa snRNP-
associated protein,
37 and, after transcriptional inhi-
bition, for TLS.
47 Such nuclear subcompartments
might either constitute the site of normal function
of these EWS-related proteins or serve as their
reservoir. Interestingly, oncoproteins that contain
the amino terminal domain of EWS or TLS are also
targeted to the same structure
47. So far, the func-
tional relevance of this ® nding is completely
unknown.
A role for EWS and its partner genes in determining the
EFT phenotype
Figure 2 summarizes all known gene fusions involv-
ing either EWS or TLS in human malignancies. In
an NIH3T3 transformation study, the type of tran-
scription factor contributing to the chimeric gene
product determined cell morphology.
35 This obser-
vation might in part explain why only members of
the ETS transcription factor family are found in
gene fusions with EWS associated with an EFT
phenotype. However, while EWS and TLS amino
termini appear to be functionally interchangable6 H. Kovar
when fused to the transcription factor CHOP in the
in vitro model,
35 as well as in myxoid chondrosar-
coma,
33,34,48 TLS has never been found to replace
EWS in EFT. In contrast, fusion of TLS to the ETS
family member ERG, which is involved in 10% of
EFT, has been reported for poor prognosis, t(l6;21)
positive, acute myeloid leukemia.
49± 51 Rearrange-
ment of EWS with other transcription factor genes
such as ATF1, the Wilms’ tumor gene WT1 and the
nuclear receptor CHN/TEC have been shown to be
associated with malignant melanoma of soft parts,
desmoplastic small round cell tumor and myxoid
chondrosarcoma, respectively.
52± 55 Thus, it is the
speci® c combination of EWS with a subset of ETS
transcription factor genes and/or a particular stem
cell in which these genes are sensitive to illegitimate
recombination that determine the EFT phenotype.
Accessibility to rearrangement by an as yet
unde® ned recombinase might also determine the
incidence of EFT. Zucman et al. reported recently
that sequence analysis of the entire EWS intron 6
region close to the major break-point region in EFT
from Caucasian origin revealed a very high density
of Alu elements resulting from repeated retroposi-
tion during evolution.
56 The Alu family of short
interspersed repetitive DNA elements has previously
been demonstrated to be frequently involved in
human gene rearrangements.
57 This region was
found to be reduced by 50% due to deletion in the
African population. This inter-ethnic polymorphism
in the EWS gene is accompanied by a striking
difference in the incidence of EFT between popula-
tions of European and African origin.
58,59 It should
be noted that the majority of EWS genomic break-
points occur in intron 7 and that intron 6 is, in fact,
never directly rearranged in EFT. So far, only three
EWS genomic break-points have been sequenced,
two in EFT and one in a desmoplastic small round
cell tumor,
60± 62, none of which contained Alu ele-
ments in the immediate vicinity of the rearrange-
ment sites. Thus, direct proof for the involvement of
Alu elements in EWS translocation is not available.
In the published cases, the lack of uniformity of
sequences affected by the gene rearrangement does
not allow the identi® cation of a speci® c recombinase
responsible for the translocation. Chromosome 22
alteration may occur as the only cytogenetically
visible aberration in EFT suggesting that the EWS±
ETS gene rearrangement is not the consequence of
a general genomic destabilization. However, the fre-
quent involvement of more than two chromosomes
in complex chromosome 22 aberrations and evi-
dence for deletion of considerable amounts of
sequences from the directly involved genes on the
untranscribed counterpart of the derivative chromo-
some 22
60 imply a complex mechanism for gene
rearrangement in EFT. In addition, while EWS and
FLI1 are equally oriented on the long arms of chro-
mosomes 22 and 11 from the centromere to the
telomere allowing for simple reciprocal transloca-
tion, the ERG gene is oriented in the opposite
direction. Consequently, EWS± ERG gene fusions
may result from either interstitial deletion/insertion
mechanisms
63 or from complex genomic rearrange-
ments involving additional chromosomes.
24
Although a high variability in EWS fusion partners
and genomic break-point locations has been noted,
rearrangement of EWS intron 7 with intron 5 or 4 of
the ETS family gene FLI1 predominates (about
80% of EFT cases).
16,18,24 Interestingly, the only
known three cases of fusion between EWS and the
ETS transcription factor gene FEV involve EWS
intron 10 which is otherwise affected in only 9% of
EFT. Since, as outlined later, the minimal portions
of EWS and its fusion partners contained in all
EFT-derived oncoproteins and required for full in
vitro transformation and transcription activation
function are signi® cantly smaller than the portions
present in the most frequently observed EWS
fusions, it is unlikely that in EFT rearrangement
sites are determined by functional constraints only.
Rather, genomic structure and accessibility might
direct illegitimate recombination to speci® c regions
in the involved genes. Genomic accessibility and
availability of recombinases might vary during the
development of speci® c stem cell lineages. There-
fore, it cannot be excluded that the different EWS
rearrangements de® ne different histogenetic starting
points of EFT development. This model would
provide an intriguing explanation for our recent
observation of prognostic differences in EFT corre-
lating with different EWS fusion types.
18 Alterna-
tively, the various chimeric oncoproteins might
display functional differences. Since the complete
EWS and FLI1 genes have been cloned and
sequence information is readily available,
64± 65 the
description of more genomic rearrangement points
in EFT will hopefully throw more light on the
mechanism of gene rearrangement in this disease.
The ETS partner in the EWS fusion gene
The ETS transcription factor family currently
counts more than 30 members. It is characterized by
the presence of a unique DNA binding domain
which is highly conserved from ¯ ies to humans and
has been ® rst described for the viral oncogene v-ets
of avian erythroblastosis virus E26 (E twentysix
speci® c). Several ETS subfamilies can be de® ned on
the basis of evolutionary sequence conservation. In
ET, 95% of cases show EWS fusion to the FLI1
(Friend leukemia virus integration site 1)/ERG
(ETS related gene) subfamily of transcriptional acti-
vators.
16,18 These two gene products share, in
addition to almost identical DNA binding domains,
a 16-amino acid stretch immediately upstream of
the ETS domain which is 100% conserved between
Xenopus and humans, suggesting an important but
as yet unidenti® ed functional role.
66 This portion is
retained in almost all EWS± FLI1 and EWS± ERGMolecular biology of Ewing tumors 7
Fig. 2. Tumor-speci® c rearrangements between an EWS
family gene and a transcription factor gene.
ETS1, GABPa , and FLI1 have recently been
demonstrated to bind to the transcription factor
PAX5 in vitro.
78 A ¯ anking PAX5 binding site
allowed for ETS1 binding to an imperfect ETS
recognition motif indicating that cooperativity might
change ETS binding speci® city to some extent.
Some ETS proteins, including ETS1, ETS2, FLI1,
ERG, GABPa and TEL, share a further conserved
region ¯ anking the amino terminal transactivation
domain, refered to as the `pointed or B-domain’.
This structure has been shown to de® ne a speci® c
oligomerization interface. For TEL, it governs
homotypic aggregation.
79 No interaction partner has
been de® ned for FLI1 and ERG so far. The con-
served fold of the amino terminal domain of ETS
proteins is, however, likely to underlie a conserved
function. Thus, replacement of this portion by the
EWS amino terminus may alter not only quantita-
tively but also qualitatively the transcriptional acti-
vation properties of these two ETS family members
by placing them into a different protein context. In
addition, several ETS family members have been
demonstrated to be a target for the RAS/RAF MAP
kinase signaling pathway. For ETS1, ras regulation
involves phosphorylation of residues within the
amino terminal `pointed’ domain. So far, no link
between this signalling pathway and FLI1 or ERG
has been reported. Consequently, it remains unclear
if fusion to EWS will uncouple FLI1/ERG target
gene regulation from extracellular signaling.
In about 1% of ET cases, EWS is rearranged with
FEV (® fth Ewing’s tumor variant) on chromosome
2.
21 This ETS family member displays 90% identity
to FLI1 in the DNA binding domain but the FLI1-
and ERG-speci® c ¯ anking 16 amino acid sequence
is missing in this protein. Interestingly, FEV also
lacks an amino terminal transactivation domain pre-
sent in most other ETS family members. Instead, it
carries a long C-terminus which, because of the
presence of abundant alanine residues, might serve
as a putative repressor domain. However, exper-
imental proof for such an activity is not yet avail-
able. Since this portion is retained in the EWS
fusion, it remains to be established if the gene
rearrangement would result in a functional conver-
sion to an activator. Interestingly, germ-line FEV
cDNA has been cloned from an EWS± FLI1 express-
ing Ewing tumor cell line, indicating coexpression of
the two genes within the same cell. If EWS± FLI1
and FEV target the same genes and FEV operates as
a repressor, it is possible that the EFT gene
rearrangement results in the release of these genes
from transcriptional inhibition by competitive bind-
ing.
So far, three cases of suspected EFT have been
reported in which EWS was fused to ETS family
genes of a different subclass on chromosomes 7p22
and 17q21, ETV1 (ETS translocation variant 1) and
E1AF (Adeno virus E1A enhancer binding factor),
the putative human homologues of mouse ER81 and
fusions, while the genuine FLI1 and ERG transacti-
vation domain is always replaced by the EWS amino
terminus resulting in a potentiation of transcrip-
tional activation properties.
67± 69 The 85-amino acid
DNA binding domain folds into three helices and
a four-stranded û sheet (winged helix-turn-helix
motif),
70± 72 most frequently refered to as `the ETS
domain’. In some ETS family members, this
domain is ¯ anked by auto-inhibitory a helical struc-
tures that fold back and interact with the ETS
domain.
73 Structural studies on murine ETS1 sug-
gest that upon speci® c binding to DNA a conforma-
tional change takes place that might expose distinct
portions of the ETS domain and its ¯ anking regions
for interactions with other proteins.
74 DNA binding-
dependent complex formation with other transcrip-
tion factors mediated by the ETS domain and
additional residues has been reported for several
ETS family members including GABP~ , ELK1,
SAP1, Pu1, ETS1 and ETS2.
75 As demonstrated
for ETS1, when binding to the speci® c recognition
sequence, intercalation of a tryptophan into the
minor groove induces a sharp kink and a widening
of DNA that might facilitate synergistic binding of
other regulatory proteins.
76 Since almost all ETS
proteins bind to a (G/C)(A/C)GGA(A/T)T consen-
sus motif,
75,77 synergy with other transcription fac-
tors might determine target speci® city of the
individual ETS family members. Interestingly,8 H. Kovar
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PEA3, respectively.
19,20,23 Most notably, the DNA
binding domains of these two transcription factors
diverge from FLI1, ERG and FEV by 38% includ-
ing the third a -helix that contacts the central core of
ETS binding sequences. Do EWS± ETV1 and
EWS± E1AF chimeric transcription factors target the
same genes as EWS± FLI1, EWS± ERG and EWS±
FEV? By a subtractive cloning strategy for genes
differentially expressed in EWS± FLI1-transformed
and FLI1-transfected untransformed murine
® broblasts (NIH3T3), several potential EWS± FLI1-
speci® c target genes were identi® ed.
80 Among them
were the murine homologue of cytochrome P-450
F1, cytokeratine 15, a novel SH2 domain containing
protein, EAT2 (EWS± FLI1 activated transcript 2)
81
and the stromelysin gene. Stromelysin is a matrix
metalloproteinase involved in metastatic invasion.
Previously, E1AF has been demonstrated to regu-
late the stromelysin gene. In transfection experi-
ments, E1AF was suf® cient to confer an invasive
phenotype to non-metastatic human breast cancer
cells (MCF7)
82 and antisense RNA to E1AF was
able to revert it in a squamous cell carcinoma cell
line.
83 Stromelysin has also been demonstrated to be
activated by ETS2, a member of another ETS sub-
family.
84 However, coexpression of ERG, which also
strongly binds to the same promoter but is by itself
unable to activate it, resulted in inhibition of ETS2-
mediated stromelysin gene activation.
85 Thus, dif-
ferent ETS family members, irrespective of their
subclass, appear to compete for binding to speci® c
target genes. It is likely, therefore, that target selec-
tivity and the speci® c mode of gene regulation by
the EWS chimeric ETS transcription factors
strongly depends on the cellular background. A
spectrum of ETS-related gene products coexpressed
with EWS± FLI1 in EFT cell lines by ampli® cation
of ETS DNA binding domain encoding cDNAs has
recently been de® ned using degenerate primers.
86
Among them, ETS2, E4TF1-60, ELK, ELF1, the
putative human homologue of ER71, and a novel
gene product ELFR were identi® ed.
127 None of the
ETS family members involved in EFT-speci® c gene
rearrangements were found to be expressed in their
germ-line con® guration. This assay, however, may
have missed low level expression of some ETS fam-
ily members (i.e. FEV). As shown in Fig. 3 compar-
ing the DNA binding domains of the ETS gene
products alternatively fused to EWS in EFT with
those found to be coexpressed with the chimeric
transcription factors, ELK is the most likely ETS-
related gene product that might interfere with the
EFT fusion proteins in target site selection because
the DNA-contacting third a -helix of the ETS
domain is identical to that of FLI1, ERG and FEV.
ELK is one of several alternative ternary complex
factors regulating a number of growth factor
inducible genes.
87 In fact, EWS± FLI1 can replace
ELK within the ternary complex formed on the
serum response element of the cfos and the EGR1
promoters.
88,89 In contrast to germ-line FLI1, bind-
ing of EWS± FLI1 to the serum response element
did not require interaction with the serum response
factor SRF. Ternary complex formation by FLI1
and EWS± FLI1 was mediated by a domain preced-
ing the DNA binding domain and present in the
majority of EFT-derived EWS± FLI1 fusions that
show limited similarity to the ELK1± SRF interac-
tion domain. However, no homologous structure
can be identi® ed in ERG and evidence for EWS±
ERG involvement in ternary complex formation is
not available.
In summary, current knowledge about normal
and aberrant ETS proteins suggest a number of
interesting candidate target genes for the EFT-
speci® c chimeric transcription factors, potentially
involved in the regulation of cell growth, signaling
and metastasis, as revealed by the study of het-
erologous cellular systems such as murine
® broblasts. However, ample evidence exists that
ETS transcription factor action is largely context
speci® c. For EFT, the cell of origin remains a
matter of speculation. Because of limited neural
differentiation potential, EFT is considered as de-
rived from the neuroectoderm.
90 Interestingly,
Xenopus FLI1 has been shown to be expressed in a
restrictive pattern during embryogenesis evocative of
neural crest cell invasion.
66 It is therefore speculated
that FLI1 might be involved in neural differentiation
in the context of these early stem cells. If so,
unscheduled activation of FLI-responsive genes by
the EFT-speci® c EWS fusion proteins in an undif-
ferentiated cell possibly unrelated to the neural crest
might result in limited neural differentiation of the
EFT stem cell depending on the degree of determi-
nation achieved at the time of gene rearrangement.
1
This model could explain the variable degree of
neuroectodermal marker expression in ES and
pPNET as well as the occurrence of biphenotypic
tumors.
26
The rate-limiting (® rst) hit in EFT pathogenesis
EWS± ETS gene rearrangements are the only genetic
aberrations that have so far been identi® ed as highly
associated with histologically diagnosed EFT. This
association is the only available compelling argu-
ment that EWS± ETS gene rearrangements can be
rate-limiting for tumorigenesis. Although comple-
mentary experimental evidence supports this
assumption, the mechanism of malignant transform-
ation by these chimeric oncoproteins remains elus-
ive. The best studied biological model for the
pathogenic role of inappropriately activated FLI1 is
Friend murine leukemia virus(F-MuLV)-induced
erythroleukemia. Insertional activation of the FLI1
gene appears to be the ® rst detectable genetic
change associated with this disease. The association
between the detection of FLI1 rearrangement and
clonal outgrowth of erythroleukemia cells suggests10 H. Kovar
that the activation of this transcription factor may be
affecting the self-renewal potential of the infected
erythroid progenitors. However, leukemogenesis
proceeds in multiple steps and additional aberra-
tions affecting viability of cells (e.g. inactivation of
the tumor suppressor gene p53) can be observed in
F-MuLV induced erythroleukemia.
91,92 In contrast
to ERG,
93 normal FLI1 was reported to be unable
to transform murine ® broblasts (NIH3T3) while
expression of an EWS fusion protein resulted in
pronounced anchorage-independent clonogenicity
of NIH3T3 cells.
94,95 However, rat embryo
® broblasts and some murine ® broblast subclones
were resistant to EWS± FLI1-mediated transform-
ation. These ® ndings again suggest that the onco-
genic potential of normal and aberrant FLI/ERG
ETS subfamily members may depend on a cell
type-speci® c availability of relevant synergistic fac-
tors and possibly on the presence of additional
aberrations. NIH3T3 transfection studies with vari-
ous recombinant EWS± FLI1 deletion mutants
revealed a dependence of transformation on both
the EWS portion and the ETS domain.
95 However,
optimal transactivation potential mediated by the 30
EWS amino terminal degenerate repeats included in
almost all EFT-derived fusion proteins was dispens-
able for maximal focus formation of transfected
NIH3T3 in soft agar. The minimal EWS domain
required to transform murine ® broblasts was delin-
eated to the ® rst 82 amino acids.
94 Recently, evi-
dence obtained shows that within the EWS± FLI1
fusion protein, but not within germ-line EWS, this
peptide directly contacts a component of the RNA
polymerase II complex, RPB7, and that this interac-
tion is suf® cient to drive EWS± FLI1-mediated
reporter gene transactivation.
125 Interactions of full-
length EWS with the general transcription factor
TFIID, an essential component of the transcrip-
tional preinitiation complex, were absent from EWS
fusion proteins.
126 It is therefore possible that fusion
of the EWS amino terminus to the FLI1 DNA
binding domain alters the protein conformation and
directly recruits RNA polymerase II to FLI1 target
genes. Since RPB7 displays similarities to prokary-
otic sigma factors, it might be involved in EFT-
speci® c target site selection. Further protein± protein
interactions presumably occurring downstream of
the 82 amino acids might be required for ef® cient
gene regulation within the EFT context. In
addition, using the yeast two-hybrid protein interac-
tion trap, further candidate proteins not directly
related to transcription regulation were identi® ed
that interacted with the 82 amino acids long mini-
mal transformation domain. These interactions
await detailed characterization.
Since no tissue of EFT origin has been identi® ed
so far, transformation studies of authentic EFT stem
cells cannot be performed. Alternatively, several
investigators have used EWS± FLI1 antagonists
(antisense RNA expression vectors, antisense
oligonucleotides, dominant negative proteins) to
modulate expression of the chimeric oncoprotein in
EFT cell lines.
86,96± 98 These studies revealed a
growth inhibitory and anti-tumorigenic effect of
these agents. Reduction in cell growth appeared to
result from cell cycle arrest and not from reduced
tumor cell viability. Recently, EWS± FLI1-mediated
transformation of murine ® broblasts was demon-
strated to require the presence of a functional
insulin-like growth factor-1 (IGF1) receptor.
99
Interestingly, consistent expression of IGF1 and its
receptor was previously reported for EFT and IGF1
was demonstrated to act as a potent growth factor
for EFT cells in the absence of serum.
l00± l03 This
cytokine appears to regulate negatively several
mechanisms of programmed cell death at a far
downstream step.
104 It has been shown that inhi-
bition of the IGF1 autoregulatory circuit by anti-
IGF1 receptor antibodies resulted in increased
apoptosis and reduced tumorigenicity of EFT
cells.
l03 Taken together, the EWS± ETS gene
rearrangement appears to be involved in the aber-
rant self-renewal capacity of EFT cells but might
not be suf® cient to guarantee survival of initiated
tumor cells. However, as demonstrated recently,
there might still be some role for FLI1, ERG and
their EWS fusions to play in the protection from
stress (i.e. calcium ionophore and serum depri-
vation)-induced cell death.
105
The second hit
Assuming that the EWS± ETS gene rearrangement is
able to initiate EFT pathogenesis but is not
suf® cient to generate malignant transformation, the
presence of additional mutations must be postu-
lated. These aberrations might not necessarily be
tumor speci® c but may display inter-individual vari-
ation that could account for variations in EFT phe-
notype as well as in clinical behavior. Also, they may
determine differentiation capacity, invasive potential
and treatment resistance. Consequently, while from
a clinical point of view the EWS± ETS gene
rearrangement provides a valuable diagnostic tumor
marker, knowledge about the nature of additional
aberrations in EFT may assist subclassi® cation and
provide prognostic tools. Since studies on facultative
genetic anomalies in EFT have been largely
neglected since the discovery of the EWS± ETS gene
rearrangements, enhanced efforts to de® ne the mul-
titude of additional aberrations are warranted for the
bene® t of patients.
Clues from cytogenetics
In three independent reviews of cytogenetically
informative EFT cases, non-random numerical and
structural chromosomal aberrations were reported
to occur with variable frequencies in addition to theMolecular biology of Ewing tumors 11
tumor speci® c t(11;22)(q24;q12)
106± 107 (Hattinger et
al., unpublished). These include trisomy 8 in about
50% of cases frequently coupled with trisomy 12
occurring in roughly 20%, and a derivative chromo-
some 16 as a result of an unbalanced t(1;16) in 18%
of EFT. In rarer cases, other aneuploidies have
been identi® ed. Structural chromosome 1 aberra-
tions that either result in gains of chromosome
1q21± 22 or relative losses of the short arm of chro-
mosome 1, a frequent alteration in neuroblastoma
and other neuroectodermal tumors, have also been
observed in EFT (Hattinger et al., unpublished).
Interestingly, this chromosomal region harbours a
gene encoding a protein (p73) that is structurally
and functionally related to the tumor suppressor
p53, a transcription factor involved in the regulation
of cell growth and apoptosis, and frequently inacti-
vated during the progression of many tumors.
108,109
While research currently focuses on the role of
p73 for neuroblastoma pathogenesis, its relevance
for a subset of EFT is something that has to be
explored.
In general, excluding chromosome 22q12 translo-
cations, numerical chromosome changes are the
most frequent cytogenetic ® ndings in EFT. These
are likely to affect gene dosage. However, no candi-
date genes that could promote EWS± ETS-initiated
EFT pathogenesis when expressed at aberrant levels
have been identi® ed so far. Also, information on
genes affected by the recurrent chromosome 16 and
1 structural alterations is not available yet. Fre-
quently, these cytogenetic alterations occur in only a
subpopulation of neoplastic cells within the tumor
suggesting that they may be associated with late
stages of tumor progression.
The role of non-speci® c cancer genes
In the absence of recurrent candidate progression-
associated genetic alterations identi® able in EFT by
the means of cytogenetics, work has focused on the
analysis of mutations generally associated with a
broad range of human malignancies. Genes investi-
gated during the last years include the oncogenes
ras, cmyc and MDM2, the tumor suppressors p53,
p16, and Rb, the metatasis-associated splice
variants of the CD44 adhesion molecule, and
the tumor-speci® c metastasis suppressor gene
nm23H1.
110± 113,127 None of the studied oncogenes
was found to be altered by mutation or in expression
although occasional low level ampli® cation of
MDM2 has been reported in an independent study
on a similar sized cohort of EFT patients.
111 Neither
mutation nor differences in expression levels of the
nucleotide diphosphate-kinase nm23H1 were
observed irrespective of the disease extension.
112
Only standard CD44 expression was detectable in
EFT.
127 In contrast, homozygous deletions of the
p16 tumor suppressor was identi® ed in about one-
third of primary EFT samples. This ® nding was
surprising since chromosomal aberrations of band
9q21 containing the p16 gene were not reported
before suggesting a high-frequency of microdele-
tions. Expression studies on EFT cell lines sug-
gested that the frequency of p16 inactivation might
be even higher since post-transcriptional gene
silencing was observed in several cases.
113 p16 acts
as an inhibitor of the cyclin D1/cyclin-dependent
kinase 4 (CDK4) complex that inactivates the cell
cycle inhibitor pRb by phosphorylation. Inactivation
of p16 should compromise the G1 cell cycle check-
point. Over-expression of either cyclin D1 or
CDK4, or loss of pRb function, is believed to medi-
ate a similar effect.
114 In fact, we observed frequent
cyclin D1 over-expression as well as variable CDK4
abundancy in EFT cell lines and loss of Rb in one
case. However, expression data from primary tumor
material are not available yet. In addition, low level
CDK4 ampli® cation was previously reported for two
of 30 EFT samples.
111
In virally induced malignancy, G1 check-point
control is frequently compromised by concomittant
inactivation of the pRb and p53 pathways. In
addition, F-MuLV-induced erythroleukemia in-
volves not only the activation of the FLI1 oncogene
as a rate-limiting step but also mutation of p53. The
author and others have, therefore, investigated the
status and expression of p53 and related genes in
EFT.
110,115 The frequency of p53 mutations in pri-
mary tumors was found to be lower than 10% as
opposed to a mean frequency of 40± 60% in most
human malignancies. In contrast, in about half of
EFT cell lines, the p53 gene was mutated and
showed loss of heterozygosity. Comparison of p53
gene status between cell lines and the respective
primary tumors of origin, when available, demon-
strated that the observed increase in mutation fre-
quency was due to selection and was not acquired
during in vitro expansion of tumor cells. This result
suggested that p53 mutation might release EFT cells
from some in vivo growth or survival factor depen-
dency. Transient transfection and over-expression of
wildtype p53 in cell lines with endogenous mutant
or wildtype gene status demonstrated frequent but
variable reduction in apoptotic responsiveness,
116
suggesting the presence of some as yet unidenti® ed
cell-protective mechanism in EFT cell lines. Prelim-
inary expression analysis of members of the cell
death regulatory Bcl2 gene family did not reveal any
signi® cant variations between individual EFT cell
lines (our unpublished observations). Previously,
high levels and activity of poly(ADP-ribose) poly-
merase, a nuclear enzyme that participates in DNA
replication, repair and the triggering of apoptosis
induced by DNA strand breaks, have been reported
for some EFT cell lines.
117 Sensitivity of EFT cell
lines to DNA damaging agents (etoposide, actino-
mycin D, X-rays) varied considerably in a manner
independent from p53 responsiveness and endoge-
nous p53 gene status suggesting that complete12 H. Kovar
mutational or partial inhibition of the p53 apopto-
sis pathway in EFT cell lines plays a role different
from radio- and chemosensitivity. However, the
physiological signals that stimulate p53-dependent
cell death have not been de® ned so far.
Molecular markers of prognosis
As a result of variable break-point localization in
the involved genes, EWS± ETS gene products vary
considerably in size. Most fusions include EWS
exons 1 to 7 (89%) and FLI1 exons 6 to 9 (54%).
EWS/FLI1 exon 7/6 fusions (type 1) predominate
independent of the disease extension (51%). In
about one-third of EFT, FLI1 exon 5 is included
into the chimeric gene product, most frequently
joined to EWS exon 7 (type 2) (27%). In rare
cases, the chromosomal translocation results in the
inclusion of EWS exons 9 (1%) or 9 plus 10 (10%)
or FLI1 exon 4 (1%). In about 3% of cases, FLI1
exon 6 or exon 6 plus 7 are missing from the gene
fusion. This variability has prompted us to investi-
gate a possible prognostic impact of the gene fusion
type. The study, performed on 55 patients with
localized disease and 30 patients with metastases at
diagnosis, treated according to the European Inter-
group Coordinated Ewing’s Sarcoma Studies
(CESS 86 and EICESS 92), revealed a signi® cantly
better outcome for patients with localized disease
carrying a type 1 EWS± FLI1 expressing tumor as
compared to non-type 1 cases.
18 A recent update
after a median observation time of 3
1
2 years
con® rmed this result (Zoubek et al., unpublished).
In addition, an independent American study per-
formed on a similar sized cohort of patients after a
median follow up of 31 months, using a similar
treatment regimen, not only supported our ® ndings
but also identi® ed the EWS± ETS gene fusion type
as a prognostic marker independent from the pres-
ence of metastases at diagnosis in a multi-variate
analysis.
128 About 55% of the `non-type 1’ group in
the two studies were comprised of type 2 gene
fusions. Because of the low incidence of the indi-
vidual `other-gene’ fusion types, no distinction has
been made between various non-type 1 subgroups
so far. In the absence of a biological explanation
for the observed prognostic differences, large col-
laborative prospective studies are warranted to
highlight the speci® c chimeric molecules and the
protein domains associated with adverse patients’
outcome.
Still, about 20% of patients with localized
tumors and more than half of the patients with
metastases succumb from the disease despite the
expression of a type 1 EWS± FLI1 gene fusion, sug-
gesting the existence of additional adverse factors.
Comparison of pl6 gene status and clinical
course of 23 EFT patients analyzed so far sug-
gested an adverse prognosis associated with this
aberration independent from the extension of the
disease.
113 These results, which have not been sub-
jected to statistical analysis, must be considered as
preliminary since patients’ numbers in the study
were small and the median observation period did
not exceed 2 years. Retrospective immunohisto-
chemical analysis of biopsy material from a large
number of patients will help to clarify the prognos-
tic relevance of a disrupted pRb cell cycle regula-
tory pathway in EFT. Also, mutation of p53 might
be linked to an adverse outcome, since none of the
three EFT patients from our series carrying such
an aberration survived. However, because of the
rarity of this alteration it cannot serve as a useful
prognostic marker.
A prognostic relevance for EFT of the observed
numerical and structural cytogenetic changes has
not been demonstrated with con® dence due to low
sample numbers in the studies performed so far.
Most recently, deletion at 1p36, occurring in 6/22
localized EFT, was discussed as being associated
with unfavorable outcome in this group (Hattinger
et al., unpublished).
In the absence of reliable molecular markers to
predict outcome in EFT, the presence of clinically
overt metastases at diagnosis is commonly con-
sidered as the only prognostic criterion that is used
for treatment strati® cation. The EWS± ETS gene
rearrangement as a tumor cell speci® c marker
detectable by the highly sensitive RT-PCR method
provides a powerful means for the detection of
minute numbers of circulating tumor cells that may
be the source of clinically occult micrometas-
tases.
118,119 However, except shortly after surgical
intervention,
120 mobilization of PCR detectable
amounts of tumor cells (. 1/10
6) into the blood-
stream has rarely been observed. In contrast, tumor
cells were detected at diagnosis by this method in
the bone marrow of 30% of patients with localized
disease, 50% of cases with isolated lung metastases
and all patients with bone metastases.
120,121 In a
preliminary series of 23 patients lacking clinically
overt dissemination, RT-PCR screening for bone
marrow involvement did not allow the prediction of
early relapse after a median observation time of 30
months. It is, however, necessary to recall several
factors that may affect tumor cell detection in the
bone marrow by RT-PCR: (1) tumor cell
in® ltration may be focal and bone marrow aspir-
ation may miss these sites, (2) bone marrow aspi-
rates may contain variable amounts of diluting
blood resulting in insuf® cient sensitivity, (3) pri-
mary EFT cells may differ in vitality, although
diluted tumor cells from cell lines can be detected
in blood samples even after 48 h at 4°C,
119 and
(4) bone marrow in® ltrating tumor cells may be in
a resting state and express lower levels of chimeric
EWS RNA than proliferating tumor cells. RT-PCR
measures RNA quantity rather than tumor cell
abundance. In a recent study, up to 10-fold varia-
tions in the content of chimeric EWS± ETS tran-Molecular biology of Ewing tumors 13
scripts between individual EFT cell lines have been
reported.
122 Moreover, germ-line EWS expression in
T-cells has been demonstrated to depend on the
proliferative activity.
123 Since the EFT-speci® c chro-
mosomal rearrangement places the chimeric gene
under the control of the EWS regulatory sequences,
it is possible that EWS± ETS gene expression may
also vary. Consequently, detectability of EWS± ETS
chimeric transcripts does not necessarily re¯ ect true
tumor cell content. Even if RT-PCR studies fail to
demonstrate signi® cance of positive blood or bone
marrow screening results for relapse in patients with
localized disease, the question of prognostic rel-
evance of tumor cell in® ltration remains unsolved.
To assess this problem, immunohistochemical stud-
ies may prove to be superior to RT-PCR. While
MIC2 may serve as a valuable surface marker in
tumor diagnosis, its exploitability for tumor cell
detection in hematopoietic tissue is limited.
124 The
recently discovered expression of gastrin-releasing
peptide (GRP) by all EFT cell lines and about half
of the primary tumors tested (Lawlor et al., unpub-
lished) may provide a marker that, in conjunction
with MIC2, may allow the identi® cation of EFT
cells in blood and bone marrow with increased
speci® city. The study of EWS± FLI1 transcriptional
targets may result in the identi® cation of tumor
cell-restricted immunohistochemical markers. In
order to detect positively staining cells with very low
abundance on a routine basis, automated micro-
scopic screening and consequently sophisticated
technical equipment is warranted.
Conclusions
In this review, I have summarized evidence for the
importance of studying EFT-speci® c genetic alter-
ations in an authentic cellular background. Since the
histogenesis of EFT is still enigmatic and no exper-
imental evidence for EWS± FLI-mediated tumorige-
nesis has been reported from transgenic mouse
models so far, EFT cell lines remain the only avail-
able system for such investigations. In this insti-
tution, cell lines could be established from 12 EFT
patients with well documented clinical course. If a
cell line could be expanded from the primary tumor,
all subsequent tumor samples also gave rise to a cell
line. All but one patient died from the disease
suggesting that establishing a cell line selects for
patients with adverse prognosis. In fact, non-type 1
EWS± ETS gene fusions, p16 deletions and p53
mutations were clearly increased in EFT cell lines
from 23 patients investigated. They may, therefore,
represent the most therapy-resistant subpopulation
of tumor cells despite variable in vitro sensitivity to
cytotoxic agents. Thus, EFT cell lines may serve as
a pool for the identi® cation of putative bad prognos-
tic markers. However, only large cooperative clinical
studies and multivariate statistical analysis will
help to address the question: how far can the
identi® cation of such markers translate into clini-
cally useful criteria for treatment strati® cation?
When comparing a wide spectrum of EFT-derived
cell lines for marker expression and response to
either differentiation inducing agents, growth factors
or cytotoxic compounds, an immense variability was
observed. Consequently, in order to sort out the
biological defects common to all EFT, a large panel
of genetically well de® ned cell lines will have to be
investigated. In the long term, such studies will
result in the identi® cation of EWS± ETS-speci® c
target genes and in a more detailed knowledge of the
mechanism of malignant conversion of the enig-
matic EFT precursor cell. Hopefully, for the bene® t
of the patients, this knowledge will potentially pro-
vide novel targets for therapeutic intervention.
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